87 related articles for article (PubMed ID: 15251128)
1. The role of CD30 in the pathogenesis of haematopoietic malignancies.
Al-Shamkhani A
Curr Opin Pharmacol; 2004 Aug; 4(4):355-9. PubMed ID: 15251128
[TBL] [Abstract][Full Text] [Related]
2. mRNA expression patterns indicate CD30 mediated activation of different apoptosis pathways in anaplastic large cell lymphoma but not in Hodgkin's lymphoma.
Staber PB; Noehammer C; Dürkop H; Schauer S; Kenner L; Linkesch W; Hoefler G
Leuk Res; 2006 Mar; 30(3):343-8. PubMed ID: 16198418
[TBL] [Abstract][Full Text] [Related]
3. JunB induced by constitutive CD30-extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase signaling activates the CD30 promoter in anaplastic large cell lymphoma and reed-sternberg cells of Hodgkin lymphoma.
Watanabe M; Sasaki M; Itoh K; Higashihara M; Umezawa K; Kadin ME; Abraham LJ; Watanabe T; Horie R
Cancer Res; 2005 Sep; 65(17):7628-34. PubMed ID: 16140928
[TBL] [Abstract][Full Text] [Related]
4. The restricted expression pattern of the Hodgkin's lymphoma-associated cytokine receptor CD30 is regulated by a minimal promoter.
Dürkop H; Oberbarnscheidt M; Latza U; Bulfone-Paus S; Hirsch B; Pohl T; Krause H; Hummel M; Stein H
J Pathol; 2000 Oct; 192(2):182-93. PubMed ID: 11004694
[TBL] [Abstract][Full Text] [Related]
5. TRAF1 is involved in the classical NF-kappaB activation and CD30-induced alternative activity in Hodgkin's lymphoma cells.
Guo F; Sun A; Wang W; He J; Hou J; Zhou P; Chen Z
Mol Immunol; 2009 Aug; 46(13):2441-8. PubMed ID: 19540595
[TBL] [Abstract][Full Text] [Related]
6. Expression and function of CD30 on T lymphocytes.
Tarkowski M
Arch Immunol Ther Exp (Warsz); 1999; 47(4):217-21. PubMed ID: 10483869
[TBL] [Abstract][Full Text] [Related]
7. The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated JunB level in a cell type-specific manner.
Hsu FY; Johnston PB; Burke KA; Zhao Y
Cancer Res; 2006 Sep; 66(18):9002-8. PubMed ID: 16982741
[TBL] [Abstract][Full Text] [Related]
8. The CD30 gene promoter microsatellite binds transcription factor Yin Yang 1 (YY1) and shows genetic instability in anaplastic large cell lymphoma.
Franchina M; Woo AJ; Dods J; Karimi M; Ho D; Watanabe T; Spagnolo DV; Abraham LJ
J Pathol; 2008 Jan; 214(1):65-74. PubMed ID: 17973241
[TBL] [Abstract][Full Text] [Related]
9. CD30 expression in normal and neoplastic lymphoid tissue: biological aspects and clinical implications.
de Bruin PC; Gruss HJ; van der Valk P; Willemze R; Meijer CJ
Leukemia; 1995 Oct; 9(10):1620-7. PubMed ID: 7564499
[TBL] [Abstract][Full Text] [Related]
10. Elevated expression of CD30 in adult T-cell leukemia cell lines: possible role in constitutive NF-kappaB activation.
Higuchi M; Matsuda T; Mori N; Yamada Y; Horie R; Watanabe T; Takahashi M; Oie M; Fujii M
Retrovirology; 2005 May; 2():29. PubMed ID: 15876358
[TBL] [Abstract][Full Text] [Related]
11. Stimulation of CD30 in anaplastic large cell lymphoma leads to production of nuclear factor-kappaB p52, which is associated with hyperphosphorylated Bcl-3.
Nishikori M; Ohno H; Haga H; Uchiyama T
Cancer Sci; 2005 Aug; 96(8):487-97. PubMed ID: 16108830
[TBL] [Abstract][Full Text] [Related]
12. Aberrant NF-kappaB2/p52 expression in Hodgkin/Reed-Sternberg cells and CD30-transformed rat fibroblasts.
Nonaka M; Horie R; Itoh K; Watanabe T; Yamamoto N; Yamaoka S
Oncogene; 2005 Jun; 24(24):3976-86. PubMed ID: 15782119
[TBL] [Abstract][Full Text] [Related]
13. c-Jun expression and activation are restricted to CD30+ lymphoproliferative disorders.
Drakos E; Leventaki V; Schlette EJ; Jones D; Lin P; Medeiros LJ; Rassidakis GZ
Am J Surg Pathol; 2007 Mar; 31(3):447-53. PubMed ID: 17325487
[TBL] [Abstract][Full Text] [Related]
14. A critical role of CD30 ligand/CD30 in controlling inflammatory bowel diseases in mice.
Sun X; Somada S; Shibata K; Muta H; Yamada H; Yoshihara H; Honda K; Nakamura K; Takayanagi R; Tani K; Podack ER; Yoshikai Y
Gastroenterology; 2008 Feb; 134(2):447-58. PubMed ID: 18242212
[TBL] [Abstract][Full Text] [Related]
15. CD30 molecule (Ki-1 Ag): more than just a marker of CD30+ lymphoma.
Pizzolo G; Romagnani S
Haematologica; 1995; 80(4):357-66. PubMed ID: 7590507
[No Abstract] [Full Text] [Related]
16. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
Jazirehi AR; Bonavida B
Oncogene; 2005 Mar; 24(13):2121-43. PubMed ID: 15789036
[TBL] [Abstract][Full Text] [Related]
17. [Molecular mechanisms of CD30 signaling and their abnormalities].
Horie R
Rinsho Ketsueki; 2001 Nov; 42(11):1085-95. PubMed ID: 11808076
[No Abstract] [Full Text] [Related]
18. Cell membrane-specific epitopes on CD30: Potentially superior targets for immunotherapy.
Nagata S; Ise T; Onda M; Nakamura K; Ho M; Raubitschek A; Pastan IH
Proc Natl Acad Sci U S A; 2005 May; 102(22):7946-51. PubMed ID: 15905329
[TBL] [Abstract][Full Text] [Related]
19. Apoptosis in CD30-positive lymphoproliferative disorders of the skin.
Greisser J; Doebbeling U; Roos M; Mueller B; Schmid M; Burg G; Kadin ME; Kempf W
Exp Dermatol; 2005 May; 14(5):380-5. PubMed ID: 15854132
[TBL] [Abstract][Full Text] [Related]
20. Pleiotropic signal transduction mediated by human CD30: a member of the tumor necrosis factor receptor (TNFR) family.
Schneider C; Hübinger G
Leuk Lymphoma; 2002 Jul; 43(7):1355-66. PubMed ID: 12389614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
